Perceptions, attitudes, and behaviors of short-acting beta2 agonist users: an Australian cross-sectional community pharmacy-based study
- PMID: 33086885
- DOI: 10.1080/02770903.2020.1841223
Perceptions, attitudes, and behaviors of short-acting beta2 agonist users: an Australian cross-sectional community pharmacy-based study
Abstract
Background: High use of short-acting beta-2-agonist (SABA) medication is a significant problem. Attitudes and perceptions toward asthma of over-the-counter (OTC) reliever users are unknown. The study aimed to describe the asthma attitudes, perceptions, medication knowledge and information gathering behavior of people with asthma with recent high SABA use (i.e. SABA use > twice a week in the last 4 weeks) and compare them to people with asthma with no recent high SABA use.
Method: A real-world cross-sectional observational study in Australian community pharmacies was conducted; surveying patients ages ≥ 16 years requesting SABA medication OTC. Data collected included; demographics, medication usage, asthma control, asthma-related perceptions and behaviors. Data were summarized by using descriptive analyses.
Results: 375 participants completed the survey, 73.9% were high SABA users. Of the 375, 90.4% reported that their asthma symptoms were controlled or somewhat controlled and 56.0% felt that their asthma was not serious. However, only 17.6%, had controlled asthma according to GINA-defined criteria. High SABA users tended to be more anxious about their asthma and worried about its impact in the future (50.5% vs. 28.6%, p < 0.001). High SABA users were more likely to agree with the statements suggesting that asthma impacted on activities of daily living (46.6% vs. 16.3%, p < 0.001); were socially conscious about their asthma and more likely to feel embarrassed carrying (21.3% vs 9.2%, p = 0.007) and using (29.2% vs 18.4%, p = 0.036) their asthma inhaler.
Conclusion: This study revealed the extent of uncontrolled asthma and uncovered an anxious and socially conscious group of OTC SABA users. There is a need to better understand patient perceptions and their relationships to high-SABA use, to ensure targeted educational interventions are developed and implemented.
Keywords: Quality of life; education; management/control; treatment.
Similar articles
-
Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting β2-agonists: A systematic review.PLoS One. 2023 Apr 20;18(4):e0283876. doi: 10.1371/journal.pone.0283876. eCollection 2023. PLoS One. 2023. PMID: 37079594 Free PMC article.
-
Over-the-counter use of short-acting beta-2 agonists: a systematic review.J Pharm Policy Pract. 2023 Oct 9;16(1):119. doi: 10.1186/s40545-023-00627-z. J Pharm Policy Pract. 2023. PMID: 37814312 Free PMC article. Review.
-
Understanding reliever overuse in patients purchasing over-the-counter short-acting beta2 agonists: an Australian community pharmacy-based survey.BMJ Open. 2019 Aug 14;9(8):e028995. doi: 10.1136/bmjopen-2019-028995. BMJ Open. 2019. PMID: 31412998 Free PMC article.
-
Short-acting β2-agonists (SABA) overuse in asthma and patients' perceptions for this behavior.Respir Med. 2024 Sep;231:107723. doi: 10.1016/j.rmed.2024.107723. Epub 2024 Jun 25. Respir Med. 2024. PMID: 38936636
-
The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia.Adv Ther. 2024 Mar;41(3):1262-1283. doi: 10.1007/s12325-023-02746-0. Epub 2024 Feb 4. Adv Ther. 2024. PMID: 38310584 Free PMC article.
Cited by
-
Perceptions, practices, and experiences of asthma patients and community pharmacists on short-acting beta-2 agonists inhaler use: A qualitative study.J Pharm Policy Pract. 2025 Feb 4;18(1):2455065. doi: 10.1080/20523211.2025.2455065. eCollection 2025. J Pharm Policy Pract. 2025. PMID: 39911587 Free PMC article.
-
Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting β2-agonists: A systematic review.PLoS One. 2023 Apr 20;18(4):e0283876. doi: 10.1371/journal.pone.0283876. eCollection 2023. PLoS One. 2023. PMID: 37079594 Free PMC article.
-
Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a cost analysis with respect to the updated GINA treatment recommendations.BMC Pulm Med. 2024 Oct 21;24(1):524. doi: 10.1186/s12890-024-03327-9. BMC Pulm Med. 2024. PMID: 39434065 Free PMC article.
-
Over-the-counter use of short-acting beta-2 agonists: a systematic review.J Pharm Policy Pract. 2023 Oct 9;16(1):119. doi: 10.1186/s40545-023-00627-z. J Pharm Policy Pract. 2023. PMID: 37814312 Free PMC article. Review.
-
Expert Consensus on SABA Use for Asthma Clinical Decision-Making: A Delphi Approach.Curr Allergy Asthma Rep. 2023 Nov;23(11):621-634. doi: 10.1007/s11882-023-01111-z. Epub 2023 Nov 22. Curr Allergy Asthma Rep. 2023. PMID: 37991672 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical